C-Rad Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

C-Rad hat ein Gesamteigenkapital von SEK290.9M und eine Gesamtverschuldung von SEK0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen SEK429.4M bzw. SEK138.5M. C-Rad Das EBIT des Unternehmens beträgt SEK56.7M, so dass der Zinsdeckungsgrad -12.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von SEK147.0M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

SEK 0

Verschuldung

Zinsdeckungsgrad	-12.8x
Bargeld	SEK 147.00m
Eigenkapital	SEK 290.90m
Gesamtverbindlichkeiten	SEK 138.50m
Gesamtvermögen	SEK 429.40m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher

Jun 02

Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts

Jan 30

C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue

Jul 03

Will the Promising Trends At C-Rad (STO:CRAD B) Continue?

Mar 05

Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 07

What Percentage Of C-Rad AB (publ) (STO:CRAD B) Shares Do Insiders Own?

Jan 17

Is C-Rad's (STO:CRAD B) 179% Share Price Increase Well Justified?

Dec 13

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CRAD BDie kurzfristigen Aktiva des Unternehmens (SEK388.5M) übersteigen seine kurzfristigen Passiva (SEK136.8M).

Langfristige Verbindlichkeiten: CRAD BDie kurzfristigen Vermögenswerte des Unternehmens (SEK388.5M) übersteigen seine langfristigen Verbindlichkeiten (SEK1.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CRAD B ist schuldenfrei.

Schulden abbauen: CRAD B hatte vor 5 Jahren keine Schulden.

Schuldendeckung: CRAD B hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: CRAD B hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

C-Rad Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher

Investor sentiment improves as stock rises 16%

C-Rad AB (publ) Appoints Mats Thorén as Board Member

Full year 2023 earnings: EPS and revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Returns On Capital Are A Standout For C-Rad (STO:CRAD B)

C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Do C-Rad's (STO:CRAD B) Earnings Warrant Your Attention?

Price target increased by 12% to kr58.00

C-Rad AB (publ)'s (STO:CRAD B) Popularity With Investors Is Clear

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

Price target increased by 13% to kr65.50

Third quarter 2023 earnings: Revenues exceed analyst expectations

Is Now The Time To Look At Buying C-Rad AB (publ) (STO:CRAD B)?

Investor sentiment improves as stock rises 19%

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

Consensus EPS estimates fall by 14%

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased by 11% to kr57.75

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

Are Investors Undervaluing C-Rad AB (publ) (STO:CRAD B) By 45%?

Price target decreased to kr62.50

C-Rad AB (publ) Announces CFO Changes

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Feb 02, 2024

Price target decreased to kr62.50

C-RAD Launches New Updated eDucation Portal as an Online Platform

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analyst expectations

Is Now An Opportune Moment To Examine C-Rad AB (publ) (STO:CRAD B)?

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Chief Financial Officer recently bought kr93k worth of stock

Consensus EPS estimates fall by 41%

Price target decreased to kr72.50

First quarter 2022 earnings: Revenues miss analyst expectations

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

Insufficient new directors

Insufficient new directors

Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts

Full year 2021 earnings: EPS and revenues miss analyst expectations

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

Price target increased to kr82.00

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

Will the Promising Trends At C-Rad (STO:CRAD B) Continue?

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

New 90-day high: kr60.30

President of China exercised options to buy kr1.5m worth of stock.

Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?

C-Rad and With-Global Engages in a Partnership for the South Korean Market

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

New 90-day high: kr56.00

What Percentage Of C-Rad AB (publ) (STO:CRAD B) Shares Do Insiders Own?

C-RAD Receives Order for Proton Cancer Treatment Centers in the US

Shenzhen Proton Therapy Treatment Center Selects C-Rad Catalyst™ System

C-Rad AB (publ) to Report Q2, 2021 Results on Jul 29, 2021

New 90-day high: kr40.75